Expression and significance of S100P, CD147, and OCT4 in different prostate cancer tissue TNM stages

Abstract

ABSTRACT. The aim of this project was to investigate the expression and significance of S100P, CD147, and OCT4 in prostate cancer tissue at different TNM stages. We enrolled 54 patients with prostate cancer, 40 with benign prostatic hyperplasia, and 20 subjects with normal prostates. S100P, CD147, and OCT4 were detected by immunohistochemistry. The positive rate of S100P detection was 18.52% in prostate cancer tissues, significantly lower than in normal and benign prostate hyperplasia tissues (P ˂ 0.05). The positive expression rate of CD147 and OCT4 were 100 and 77.38% in prostate cancer tissue, respectively, both markedly higher than in normal and benign prostate hyperplasia tissue (P ˂ 0.05). The positive rate of S100P in stage V was 0, which was significantly lower than in stages I (37.50%) and II (35.71%) (P ˂ 0.05). OCT4 expression in stages III (86.67%) and V (94.12%) was higher than in stage I (37.50%). The positive rate of S100P in patients with distant metastasis was 4%, which was significantly lower than that in patients without metastases 6845 S100P, CD147, and OCT4 in prostate cancer ©FUNPEC-RP www.funpecrp.com.br Genetics and Molecular Research 14 (2): 6844-6851 (2015) (P ˂ 0.05). In contrast, the positive rate of OCT4 in patients with distant metastasis was 92%. S100P, CD147, and OCT4 expression in prostate cancer patients with different degrees of differentiation had no significant difference (P > 0.05). Overall, our results demonstrated that S100P expression in prostate cancer tissue was significantly decreased, whereas CD147 and OCT4 expression was increased. Their expression levels were closely associated with TNM stage and distant metastasis, but were not related to the degree of differentiation.

SNP at miR-483-5p-binding site in the 3'-untranslated region of the BSG gene is associated with susceptibility to esophageal cancer in a Chinese population

“…Moreover, CD147 promotes proliferation, stimulates proteolytic enzyme expression, induces vascular endothelial growth factor expression and angiogenesis, and enables anchorage-independent growth (Bordador et al, 2000;Tang et al, 2005). For example, Wang et al (2015) reported that CD147 plays a role in proliferation, invasion, and chemosensitivity of the human gastric cancer cell line SGC7901. Therefore, a thorough understanding the CD147 biology and proteins interacting with BSG will have a significant impact on our understanding of the development of cancer.…”

“…Cluster of differentiation 147 (CD147) or extracellular matrix metalloproteinase inducer (EMMPRIN), also known as basigin (BSG), is a highly glycosylated transmembrane protein with increased expression in many forms of malignancy (Wang et al, 2015). CD147 induces the production of matrix metalloproteinases, a group of proteins that can degrade the extracellular matrix, in adjacent interstitial normal cells (Curran and Murray, 2000;Gabison et al, 2005).…”

CD147 and Prostate Cancer: A Systematic Review and Meta-Analysis

“…A total of 15 studies [ 9 , 10 , 11 , 12 , 13 , 14 , 15 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 ] were identified for qualitative analysis. The study by Bauman et al was not included in the quantitative analysis because it provided the mean optical density of CD147 and not the positive expression rate of CD147.…”

“…The study by Bauman et al was not included in the quantitative analysis because it provided the mean optical density of CD147 and not the positive expression rate of CD147. Therefore, 14 studies [ 9 , 10 , 11 , 12 , 13 , 14 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 ] were included for quantitative analysis, including 12,591 prostate cancer tissues, 298 benign prostatic hyperplasia tissues, and 175 normal prostate tissues. Six articles provided a positivity rate of CD147 expression in prostate cancer and normal prostate tissues, 8 articles reported on CD147 expression in prostate cancer and benign prostatic hyperplasia, 12 articles involved Gleason score, 6 articles involved TNM stage, 5 articles involved differentiation, 6 articles involved lymph node metastasis, and 2 articles involved distant metastasis.…”

“…To date, there have been some case-control studies that investigated the expression of CD147 in prostate cancer. They found prostate cancer tissues had a higher positivity rate that is significantly different from prostatic hyperplasia and normal prostate tissues, and their authors concluded that the expression of CD147 is related to TNM stage, aggressiveness, distant metastasis, and prognosis of prostate cancer; however, some studies had different conclusions[ 11 , 12 , 13 , 14 , 15 ]. To provide better evidence of the clinical application of CD147 in prostate cancer patients, this meta-analysis was conducted to assess the correlation between CD147 and prostate cancer.…”